Galmed Pharmaceuticals
GLMD
Market cap $4.42M

2.93 USD

-0.17

5.48%

At close Nov 15, 4:00 PM EST

1 day

-5.48%

5 days

1.38%

1 month

-25.26%

3 months

-16.52%

6 months

-36.44%

Year to date

-44.51%

1 year

-38.96%

5 years

-99.63%

10 years

-99.72%

About: Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

Employees: 8

0

Funds holding %

of 6,704 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

6.44% less ownership

Funds ownership: 6.81% [Q2] → 0.37% (-6.44%) [Q3]

23% less funds holding

Funds holding: 13 [Q2] → 10 (-3) [Q3]

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

69% less capital invested

Capital invested by funds: $123K [Q2] → $38.3K (-$84.6K) [Q3]

86% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 7

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for GLMD.

See Analyst Rankings

Financial journalist opinion

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

The paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH) Data is confirmed using 3 objective measurements; NASH CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysis Continuous histological fibrosis scores generated in antifibrotic trials by digital pathology images analysis (DIA) quantify antifibrotic effects with greater sensitivity and larger dynamic range than Conventional Pathology TEL AVIV, Israel , Sept. 25, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Aramchol is the most clinically advanced, first-in-class, Stearoyl-CoA desaturase1 (SCD1) oral inhibitor, demonstrating in Ph2 and Ph3 (open label part) an excellent safety profile with metabolic and anti-fibrotic effects. Galmed raised an aggregate of $7.5 million in warrant exercises and drawdowns on its recently adopted equity line TEL AVIV, Israel , Sept.

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Galmed Pharma Surges 400%: What's Behind the Explosion?

Galmed Pharmaceuticals NASDAQ: GLMD, a little-known biotech stock, has become the center of attention as its shares have skyrocketed close to 400%. By 2 pm, the stock had traded over 80 million shares, a monumental leap from its average daily volume of just 75,000.

Galmed Pharma Surges 400%: What's Behind the Explosion?

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024

Now could be a great time for investors to consider stacking up on penny stocks. These companies often have significant growth potential.

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

TEL AVIV, Israel , April 4, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (the "SEC").

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

TEL AVIV, Israel , March 15, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the grant of a European patent related to the use of a combination of Aramchol and Resmetirom (MGL-3196, REZDIFFRA) for the treatment of NASH/MASH and liver fibrosis.

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

TEL AVIV, Israel , Nov. 20, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today a delay of at least 6 months in the initiation of its Primary Sclerosing Cholangitis (PSC) Ph 2a Study.

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

See News Rankings

Charts implemented using Lightweight Charts™